QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)
QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)
QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)
QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)

Eli Lilly and Company (LLY) Stock Price, News & Analysis

$735.56
+10.17 (+1.40%)
(As of 02/8/2024 ET)
Today's Range
$725.97
$740.77
50-Day Range
$570.21
$724.91
52-Week Range
$309.20
$742.00
Volume
4.64 million shs
Average Volume
3.47 million shs
Market Capitalization
$698.27 billion
P/E Ratio
126.82
Dividend Yield
0.61%
Price Target
$621.81

Eli Lilly and Company MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.79 Rating Score
Upside/​Downside
15.5% Downside
$621.81 Price Target
Short Interest
Healthy
0.58% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
-2.25
Upright™ Environmental Score
News Sentiment
0.49mentions of Eli Lilly and Company in the last 14 days
Based on 88 Articles This Week
Insider Trading
Selling Shares
$125.25 M Sold Last Quarter
Proj. Earnings Growth
39.75%
From $12.73 to $17.79 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.72 out of 5 stars

Medical Sector

54th out of 911 stocks

Pharmaceutical Preparations Industry

18th out of 424 stocks

LLY stock logo

About Eli Lilly and Company Stock (NYSE:LLY)

Eli Lilly and Company is a US-based multinational pharmaceutical company. It is the 12th largest pharmaceutical company by revenue and has offices in 16 countries. Its medicines are sold in at least 125 countries including its 8 blockbuster drugs. The company is a member of the S&P 500 and S&P 100 indices, it brought in roughly $5.5 billion in revenue for 2021 and employs more than 35,000 people across its network of research and production facilities.

Eli Lilly and Company was founded in 1876 by Colonel Eli Lilly. The colonel, a veteran of the Civil War, had recently dissolved an unsatisfactory partnership and set on his own to produce and develop medicinal chemicals. Colonel Lilly remained as president until his death in 1898. His charge to his family, company and coworkers was to “take what you find here and make it better and better”. The company is well-known for many drugs, including the first mass-marketing of quinine to treat malaria.

The company brought in $4,470 in its first year and saw that figure grow 10X over the next 3. Among the many innovations during this time period is the addition of gelation coatings for pills which helped set the company up for rapid expansion. The company was incorporated in 1881 as Eli Lilly and Company issuing stock to family and friends. The 1900s brought about more change for the company, change in the form of expansion which included international markets.

Advancements during the war years included increases in efficiency due to increased automation and the development of precision technologies. Among the technologies was pill manufacturing which included injecting medicines directly into a gelation capsule. This method allowed for more exact dosing, setting the standard for modern production. The company produced capsules for itself and sold excess capacity to competitors. Other major advancements include fruit flavorings in medicine, straight-line manufacturing and a method of blueprinting manufacturing tickets to prevent errors.

The modern period saw the company grow and discover new, world-class pharmaceuticals. Today, the company is engaged in the discovery, development and marketing of human pharmaceuticals. It offers a wide range of treatments, including Prozac but is perhaps most noteworthy for its work with insulin. The company is the first to mass produce insulin and has made numerous advances in treating diabetes in the time since. While other drugs are more widely known, its diabetic drugs Basaglar, Jardience, Trulicity, Humalog and Humulin are its top-sellers and contribute the bulk of revenue and cash flow.

Along with Diabetic research, the company also focuses on Alzheimer's, Oncology, Immunology, Obesity and Pain care. At the end of 2022, the company pipeline had 23 compounds in Phase 3 clinical trials and 1 in review. There were another 18 in Phase 2 trials and more than 2 dozen in Phase 1 trials. The average cost to discover a new drug was running at $2.6 billion with a 10-year discovery-to-patient timeline.

LLY Stock Price History

LLY Stock News Headlines

Eli Lilly's formula for success: Blending innovation with insight
Eli Lilly showcases its financial strength and strategic innovation through its Q4 2023 earnings and forward-looking growth initiatives.
Weight loss, diabetes drugs propel Eli Lilly to better-than-expected forecast for 2024
The popular diabetes treatment Mounjaro pushed Eli Lilly past fourth-quarter forecasts, and the drugmaker expects 2024 to turn out largely better than expected too, as new products build momentum
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Markets suddenly price Eli Lilly stock for a breakout on earnings (LLY)
The healthcare sector could see a sudden inflow of investment dollars, and Eli Lilly quickly becomes a favorite name in the space as markets and analysts bid up
Pfizer’s earnings growth trade at a deep discount, suddenly a buy (LLY)
The healthcare sector is set to attract a new inflow of investment dollars, as seen in business activity and employment. Pfizer is the clear sector favorite
5 top healthcare stocks for earnings growth in 2024 (LLY)
2024 holds promise for healthcare stocks, with Humana, Elevance, and others expected to boost earnings, as analysts say many industry pressures have been removed.
20 best healthcare dividend stocks to invest in (LLY)
Healthcare, like many other sectors, produces dividends. Learn more about how to invest in healthcare trends and earn dividends along the way with MarketBeat.
Merck, the Dow's hottest stock, gets set to report Q4 financials (LLY)
Up 5.7% year-to-date, pharmaceuticals - including MRK - are the best performing industry in the entire U.S. equity market, outpacing even biotech stocks.
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
2 biotechs with promising weight-loss drugs coming (LLY)
Clinical weight-loss medications have been making headlines as GLP-1 drugs like Novo Nordisk A/S (NYSE: NVO) owned Ozempic and Wegovy and Eli Lilly and Co.
AstraZeneca: Rebound in 2024 with double-digit earnings growth (LLY)
AstraZeneca's stock rose 8.95% in the past month on a bullish outlook, driven by growing sales of cancer and diabetes drugs and a strategic acquisition
Where will S&P 500 go after new bullish levels? (LLY)
Major indexes look resilient despite 2024's rocky start, getting support at key moving averages. Upcoming earnings could be catalysts in either direction.
Eli Lilly and Company: Raising target price to $770
See More Headlines
Receive LLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eli Lilly and Company and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 12/8 Dividend
11/14/2023
Dividend Payable
12/08/2023
Last Earnings
2/06/2024
Today
2/08/2024
Ex-Dividend for 3/8 Dividend
2/14/2024
Dividend Payable
3/08/2024
Next Earnings (Estimated)
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
53245710
Employees
39,000
Year Founded
1876

Price Target and Rating

Average Stock Price Target
$621.81
High Stock Price Target
$865.00
Low Stock Price Target
$278.00
Potential Upside/Downside
-15.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.79
Research Coverage
19 Analysts

Profitability

Net Income
$6.24 billion
Pretax Margin
19.21%

Debt

Sales & Book Value

Annual Sales
$34.12 billion
Cash Flow
$9.56 per share
Book Value
$11.34 per share

Miscellaneous

Free Float
948,073,000
Market Cap
$698.39 billion
Optionable
Optionable
Beta
0.32

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report














LLY Stock Analysis - Frequently Asked Questions

Should I buy or sell Eli Lilly and Company stock right now?

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and Company in the last year. There are currently 1 sell rating, 2 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LLY shares.
View LLY analyst ratings
or view top-rated stocks.

What is Eli Lilly and Company's stock price target for 2024?

19 brokerages have issued 1 year target prices for Eli Lilly and Company's stock. Their LLY share price targets range from $278.00 to $865.00. On average, they expect the company's share price to reach $621.81 in the next twelve months. This suggests that the stock has a possible downside of 15.5%.
View analysts price targets for LLY
or view top-rated stocks among Wall Street analysts.

How have LLY shares performed in 2024?

Eli Lilly and Company's stock was trading at $582.92 at the beginning of the year. Since then, LLY shares have increased by 26.2% and is now trading at $735.68.
View the best growth stocks for 2024 here
.

When is Eli Lilly and Company's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our LLY earnings forecast
.

How were Eli Lilly and Company's earnings last quarter?

Eli Lilly and Company (NYSE:LLY) posted its quarterly earnings results on Tuesday, February, 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.19. The firm earned $9.35 billion during the quarter, compared to analysts' expectations of $8.95 billion. Eli Lilly and Company had a trailing twelve-month return on equity of 50.78% and a net margin of 15.36%. Eli Lilly and Company's revenue was up 28.1% compared to the same quarter last year. During the same period last year, the firm posted $2.09 EPS.
Read the conference call transcript
.

How often does Eli Lilly and Company pay dividends? What is the dividend yield for Eli Lilly and Company?

Eli Lilly and Company declared a quarterly dividend on Friday, December 8th. Stockholders of record on Thursday, February 15th will be paid a dividend of $1.30 per share on Friday, March 8th. This represents a $5.20 annualized dividend and a yield of 0.71%. The ex-dividend date of this dividend is Wednesday, February 14th. This is a boost from the stock's previous quarterly dividend of $1.13.
Read our dividend analysis for LLY
.

Is Eli Lilly and Company a good dividend stock?

Eli Lilly and Company (NYSE:LLY) pays an annual dividend of $4.52 per share and currently has a dividend yield of 0.64%. The company has been increasing its dividend for 10 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 77.93%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, LLY will have a dividend payout ratio of 25.41% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LLY.

What guidance has Eli Lilly and Company issued on next quarter's earnings?

Eli Lilly and Company updated its FY24 earnings guidance on Tuesday, February, 6th. The company provided earnings per share guidance of $12.20-12.70 for the period, compared to the consensus earnings per share estimate of $12.39. The company issued revenue guidance of $40.4-41.6 billion, compared to the consensus revenue estimate of $39.27 billion.

What is David A. Ricks' approval rating as Eli Lilly and Company's CEO?

399 employees have rated Eli Lilly and Company Chief Executive Officer David A. Ricks on Glassdoor.com. David A. Ricks has an approval rating of 86% among the company's employees.

What other stocks do shareholders of Eli Lilly and Company own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly and Company investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY), Walt Disney (DIS), AT&T (T), Verizon Communications (VZ) and JPMorgan Chase & Co. (JPM).

Who are Eli Lilly and Company's major shareholders?

Eli Lilly and Company's stock is owned by a variety of retail and institutional investors. Top institutional investors include Jennison Associates LLC (0.80%), International Assets Investment Management LLC (0.77%), Charles Schwab Investment Management Inc. (0.48%), Fisher Asset Management LLC (0.48%), Dimensional Fund Advisors LP (0.36%) and Massachusetts Financial Services Co. MA (0.34%). Insiders that own company stock include Acquisition Corp Kearny, Alonzo Weems, Anne E White, Donald A Zakrowski, Ilya Yuffa, Jackson P Tai, Johna Norton, Lilly Endowment Inc, Marschall S Runge and Patrik Jonsson.
View institutional ownership trends
.

How do I buy shares of Eli Lilly and Company?

Shares of LLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Eli Lilly and Company have any subsidiaries?
The following companies are subsidiares of Eli Lilly and Company: 1096401 B.C. Unlimited Liability Company, ARMO Biosciences Inc., Acanthas Pharma Inc., Advanced Cardiovascular Systems, Alnara Pharmaceuticals, Alnara Pharmaceuticals Inc., Andean Technical Operations Center, Applied Molecular Evolution Inc., AurKa Pharma Inc., Avid Radiopharmaceuticals, Avid Radiopharmaceuticals Inc., ChemGen, CoLucid Pharmaceuticals, CoLucid Pharmaceuticals Inc., Compania Farmaceutica Eli Lilly de Centro America S.A., Dermira, Dermira Canada, Dermira Inc., Devices for Vascular Intervention(DVI), Disarm Therapeutics, Disarm Therapeutics, Disarm Therapeutics Inc., Dista Ilac Ticaret Ltd. Sti., Dista S.A., Dista-Produtos Quimicos & Farmaceuticos LDA, ELCO Dominicana SRL, ELCO Insurance Company Limited, ELCO Management Inc., ELCO for Trade and Marketing S.A.E., ELGO Insurance Company Limited, Elanco Animal Health Ireland Limited, Elanco Switzerland Holding Sarl, Eli Lilly (Malaysia) Sdn. Bhd., Eli Lilly (Philippines) Incorporated, Eli Lilly (S.A.) (Proprietary) Limited, Eli Lilly (Singapore) Pte. Ltd., Eli Lilly (Suisse) S.A., Eli Lilly Asia Inc., Eli Lilly Asia Pacific SSC Sdn Bhd, Eli Lilly Australia Pty. Limited, Eli Lilly B-H d.o.o., Eli Lilly Benelux S.A., Eli Lilly Bienes y Servicios S de RL de CV, Eli Lilly CR s.r.o., Eli Lilly Canada Inc., Eli Lilly Cork Limited, Eli Lilly Danmark A/S, Eli Lilly Egypt for Trading, Eli Lilly European Clinical Trial Services SA, Eli Lilly Export S.A., Eli Lilly Finance S.A., Eli Lilly Ges.m.b.H., Eli Lilly Group Limited, Eli Lilly Holdings Ltd., Eli Lilly Hrvatska d.o.o., Eli Lilly Interamerica Inc., Eli Lilly Interamerica Inc. y Compania Limitada, Eli Lilly International Corporation, Eli Lilly Ireland Holdings Limited, Eli Lilly Israel Ltd., Eli Lilly Italia S.p.A., Eli Lilly Japan K.K., Eli Lilly Kinsale Limited, Eli Lilly Nederland B.V., Eli Lilly Nigeria Ltd., Eli Lilly Norge A.S., Eli Lilly Pakistan (Pvt.) Ltd., Eli Lilly Polska Sp.z.o.o. (Ltd.), Eli Lilly Regional Operations GmbH, Eli Lilly Romania SRL, Eli Lilly S.A., Eli Lilly Saudi Arabia Limited, Eli Lilly Services India Private Limited, Eli Lilly Slovakia s.r.o., Eli Lilly Sweden AB, Eli Lilly Vostok S.A. Geneva, Eli Lilly and Company, Eli Lilly and Company (India) Pvt. Ltd., Eli Lilly and Company (Ireland) Limited, Eli Lilly and Company (N.Z.) Limited, Eli Lilly and Company (Taiwan) Inc., Eli Lilly and Company Limited, Eli Lilly do Brasil Limitada, Eli Lilly farmacevtska druzba d.o.o., Eli Lilly y Compania de Mexico S.A. de C.V., Eli Lilly y Compania de Venezuela S.A., Glycostasis Inc., Greenfield-Produtos Farmaceuticos Lda., Heart Rhythm Technologies Inc, Hybritech, Hypnion, ICOS Corporation, ICOS Corporation, ImClone GmbH, ImClone LLC, ImClone Systems Holdings Inc., ImClone Systems LLC, Imclone Systems, Irisfarma S.A., Ivy Animal Health, LDH I Corporation, Lilly (Shanghai) Management Co. Ltd., Lilly Asia Ventures Fund I L.P., Lilly Asia Ventures Fund II L.P., Lilly Asian Ventures Fund III L.P., Lilly Cayman Holdings, Lilly Centre for Clinical Pharmacology PTE. LTD., Lilly China Research and Development Co. Ltd, Lilly Deutschland GmbH, Lilly France S.A.S., Lilly Global Nederland Holdings B.V., Lilly Global Services Inc., Lilly Holding GmbH, Lilly Holdings B.V., Lilly Hungaria KFT, Lilly Japan Financing G.K., Lilly Korea Ltd., Lilly Nederland Finance B.V., Lilly Nederland Finance B.V. - GCC, Lilly Nederland Holding B.V., Lilly Pharma Ltd., Lilly Portugal - Produtos Farmaceuticos Lda., Lilly S.A., Lilly Suzhou Pharmaceutical Co. Ltd., Lilly Trading Co. LTD, Lilly USA LLC, Lilly Ventures Fund I LLC, Lilly del Caribe Inc., Lilly ilaç ticaret limited şirketi, Lohmann Animal Health, Loxo Oncology, Loxo Oncology Inc., Novartis Animal Health, OY Eli Lilly Finland AB, Origin Medsystems, PT. Eli Lilly Indonesia, Pacific Biotech, Petra Pharma Corporation, Pharmaserve-Lilly S.A.C.I., Pharmaserve-Lilly S.A.C.I., Physio-Control, Prevail Therapeutics Inc., Protomer Technologies, SGX Pharmaceuticals, SGX Pharmaceuticals Inc., Spaly Bioquimica S.A., UAB Eli Lilly Lietuva, Valquifarma S.A., and Vital Pharma Productos Farmaceuticos.
Read More
This page (NYSE:LLY) was last updated on 2/8/2024 by MarketBeat.com Staff

From Our Partners

My Account -